"Designing Growth Strategies is in our DNA"

U.S. Specialty Generics Market Size, Share & Industry Analysis, By Route of Administration (Injectable, Oral, and Others), By Indication (Cancer, Cardiovascular Diseases, Autoimmune Diseases, Infectious Diseases, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2024-2032

Last Updated: September 30, 2024 | Format: PDF | Report ID: FBI109232

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The U.S. specialty generics market size was worth USD 38.70 billion in 2023 and is projected to grow at a CAGR of 15.3% during the forecast period. 


Specialty generics are generic versions of specialty branded drugs once they lose their patent protection. They treat complex, chronic, or life-threatening diseases, such as cancer, rheumatoid arthritis, HIV, and multiple sclerosis. Factors, such as the increasing number of patent expirations and rising prevalence of above-mentioned diseases are projected to drive the U.S. specialty generics market growth over the forecast period.



  • For instance, as per data from the U.S. Centers for Disease Control and Prevention (CDC), in 2020, 1.60 billion new cancer cases were reported, and it is projected to grow to around 1.95 billion by the end of 2023.


Furthermore, the development of innovative distribution channels, such as telemedicine platforms and online pharmacies has also driven the specialty generics market progress. In addition, increasing focus of governments and insurance companies on incentivizing or mandating the prescription of generics when they are available is anticipated to boost the product’s demand.


The impact of the COVID-19 pandemic slowed the growth of the market in 2020 as clinical studies were put on hold due to lockdown restrictions.


U.S. Specialty Generics Market Trends


Increased Approvals for Injectable Generic Drugs


Several initiatives have been undertaken by various agencies to deliver safe and effective low-cost generic drugs to the public. In addition, key players are constantly making efforts to commercialize specialty generic drugs in the market. They are highly focused on expanding their geographical presence and product portfolio with the help of innovations. Thus, these players are receiving FDA approvals for their products.



  • For instance, in July 2023, Amneal Pharmaceuticals, Inc. announced the U.S. FDA approval for five of its complex generic products. Out of these, three recently approved products are injectables, including the dexmedetomidine injection.


The increasing product approvals provides easy access to low-cost specialty generic drugs to cancer patients, thereby increasing the prescription rate.


U.S. Specialty Generics Market Growth Factors


High Burden of Chronic Diseases and Rising Geriatric Population to Fuel Demand for Specialty Generics


Specialty generics are low-cost and do not incur development and marketing costs. The increasing adoption of specialty generic drugs among the population to treat chronic diseases and their increasing availability are some of the crucial drivers for the market growth.



  • For instance, according to data published by the CDC and Health Promotion, in January 2021, 6 in 10 adults suffered from chronic diseases in the U.S., and 4 in 10 adults had two or more chronic diseases.


Moreover, the growing geriatric population is a significant factor in the rising prevalence of chronic diseases due to weak immunity and high incidence of comorbid conditions, such as diabetes, high blood pressure, arthritis, cardiovascular disease, stroke, and other malignant illnesses. For these patients, specialty generics are used to treat such chronic diseases. The above-mentioned factors are projected to drive the growth of the U.S. specialty generics market over the forecast period.


Request a Free sample to learn more about this report.


The adult population above 50 years of age with at least one chronic disease is estimated to increase by 99.5% from 71.52 million in 2020 to 142.66 million by 2050.


RESTRAINING FACTORS


Complex Development Process of Specialty Generics


Simple generics usually have a clear development process that has proper guidelines from the FDA Office of Generic Drugs (OGD) explaining the data requirement and endpoints for U.S. approval. Companies are less likely to find regulatory guidance in complex generics, which adds risk and uncertainty to the planning and design process. Having a clear regulatory strategy that leads to product approval is crucial for specialty generics. Thus, this factor can hamper the growth of the U.S. specialty generics market share to a certain extent.


U.S. Specialty Generics Market Segmentation Analysis


By Route of Administration Analysis


Based on route of administration, the U.S. specialty generics market is segmented into injectable, oral, and others.


The oral segment held a larger market share in 2022. The market players are focused on launching oral drugs owing to their convenience in consumption. Moreover, oral drugs are self-administered and pain-free, this is responsible for the segment’s dominance in the market.



  • In July 2023, Amneal Pharmaceuticals, Inc. announced the launch of its authorized generic for Xyrem1 (Sodium Oxybate) oral solution CIII in the United States for the treatment of hypersomnia in patients with narcolepsy.


By Indication Analysis


Based on indication, the market is segmented into cancer, cardiovascular diseases, autoimmune diseases, infectious diseases, and others.


The cancer segment held the largest market share in 2022 owing to the growing number of generic drug launches for cancer treatment and increase in cancer cases. The growth in these cases is attributed to high alcohol consumption, smoking, and adoption of western lifestyle, physical inactivity, and poor diet choices. As the number of cancer cases rises, the demand for specialty generics is expected to increase.



  • For instance, in March 2022, Teva Pharmaceuticals USA, Inc. announced the launch of the first generic version of Revlimid (lenalidomide capsules), in the U.S. to treat multiple myeloma.


Moreover, the infectious diseases segment is projected to record a significant CAGR during the forecast period owing to the growing prevalence of infectious diseases, such as Hepatitis, HIV, and other conditions.


By Distribution Channel Analysis


Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.


The hospital pharmacies segment held the largest market share in 2022 owing to increasing prescription of medications at hospitals. In addition, effective distribution management and easy access to medicines at these pharmacies are driving the segment’s growth.



  • For instance, according to the data published by the NCBI, the overall spending on prescription drugs in clinics and hospitals increased from 7% to 9% and 3% to 5%, respectively in 2022, compared to 2021.


The online pharmacies segment is projected to expand at a rapid CAGR due to the ease and convenience these stores offer. Furthermore, increasing use of e-prescriptions by healthcare settings to purchase drugs through online phramacies is projected to boost the segment’s growth in the future.


List of Key Companies in U.S. Specialty Generics Market


The U.S. specialty generics market is fragmented and consists of several key players in terms of the competitive landscape. Teva Pharmaceuticals USA, Inc. and Viatris, Inc. are the prominent players in this market. Their dominance is mainly attributed to their broad product portfolios and strong brand presence.


Other companies, such as Mallinckrodt, Amneal Pharmaceuticals LLC, Viatris Inc., Endo Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and Baxter have a considerable presence in the U.S. market. These firms are focused on launching effective specialty generic drugs for people with unmet treatment needs. For instance, Amneal Pharmaceuticals, Inc. announced the launch of 26 new generic products in 2022.


LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • June 2023 – Sun Pharmaceutical Industries Ltd. increased its R&D investment in the specialty generics segment. The company’s current pipeline for generics products for the U.S. market includes 97 ANDAs, while 13 new drug applications are waiting for the U.S. FDA's approval.

  • July 2022 Elixir, a pharmacy services provider and subsidiary of Rite Aid Corp., launched a specialty generic medication to enhance its managed copay solutions.

  • January 2021 – Teva Pharmaceutical Inc. announced the launch of a generic version of NuvaRing to prevent pregnancy in women.


REPORT COVERAGE


The report provides a detailed analysis of the market. It focuses on key aspects, such as an overview of the prevalence of major chronic diseases, regulatory framework for specialty generics, and new product launches.  Additionally, it includes key industry developments, such as mergers, partnerships, acquisitions, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.


To gain extensive insights into the market, Request for Customization


Report Scope & Segmentation
















































ATTRIBUTE



DETAILS



Study Period



2019-2032



Base Year



2023



Estimated Year



2024



Forecast Period



2024-2032



Historical Period



2019-2022



Growth Rate



CAGR of 15.3% from 2024 to 2032



Unit



Value (USD Billion)



Segmentation



By Route of Administration



  • Injectable

  • Oral



  • Others



By Indication



  • Cancer

  • Cardiovascular Diseases

  • Autoimmune Diseases

  • Infectious Diseases

  • Others



By Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies






Frequently Asked Questions

Fortune Business Insights says that the U.S. market was worth USD 38.70 billion in 2023.

The market is expected to exhibit a CAGR of 15.3% during the forecast period of 2023-2030.

By indication, the cancer segment accounted for a leading share of the market.

Teva Pharmaceuticals USA, Inc. and Viatris, Inc. are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts
Speak to an Expert
  • 2019-2032
  • 2023
  • 2019-2022
  • 70
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase
Healthcare Clients
Jubilant
Johnson
iqvia
Styker
Lek
Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X